Objective: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positivepolycythemia vera (PV) and essential thrombocytosis (ET). Methods: Interferon alpha 2 b was used to treatpatients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study wasto compare rates of hematological and molecular remission. Results: Patients in the interferon alpha 2 b groupachieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, witha lower incidence of thrombosis. Conclusion: Compared with hydroxyurea, interferon alpha 2 b could reduceJAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatmentefficacy and reduce complications.
(2014). Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis. Asian Pacific Journal of Cancer Prevention, 15(4), 1681-1684.
MLA
. "Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis". Asian Pacific Journal of Cancer Prevention, 15, 4, 2014, 1681-1684.
HARVARD
(2014). 'Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis', Asian Pacific Journal of Cancer Prevention, 15(4), pp. 1681-1684.
VANCOUVER
Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis. Asian Pacific Journal of Cancer Prevention, 2014; 15(4): 1681-1684.
)